Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5178-5184

  Shelton, Mark J ^a   Lovern, Mark ^a   Ng Cashin, Judith ^a   Jones, Lori ^a   Gould, Elizabeth ^a   Gauvin, Jennifer ^a   Rodvold, Keith A ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE; ZANAMIVIR;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTINUOUS INFUSION; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIMB PAIN; LOADING DRUG DOSE; LUNG ALVEOLUS EPITHELIUM; LUNG FLUID; LUNG LAVAGE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHILIA; NONHUMAN; NORMAL HUMAN; NOSE MUCUS; PRIORITY JOURNAL; SIDE EFFECT; SORE THROAT; T WAVE INVERSION; WILD TYPE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; LUNG; MALE; MIDDLE AGED; YOUNG ADULT; ZANAMIVIR;

EID: 80053611518     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00703-11     Document Type: Article

References (18)

1. Baldwin, D. R., D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob. Agents Chemother. 36:1171-1180.
2. Calfee, D. P., A. W. Peng, L. M. Cass, M. Lobo, and F. G. Hayden. 1999. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43:1616-1620. (Pubitemid 29331237)
3. Cass, L. M. R., C. Efthymiopoulos, and A. Bye. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):1-11. (Pubitemid 29322452)
4. de Jong, M. D., et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
5. Dulek, D. E., et al. 2010. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin. Infect. Dis. 50:1493-1496.
6. Gaur, A. H., et al. 2010. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N. Engl. J. Med. 362:88-89.
7. GlaxoSmithKline. 2010. Relenza (zanamivir inhalation powder) product information. GlaxoSmithKline, Research Triangle Park, NC.
8. Gotfried, M. H., L. H. Danziger, and K. A. Rodvold. 2003. Steady-state and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J. Antimicrob. Chemother. 52:450-456. (Pubitemid 37120725)
9. Härter, G., et al. 2010. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin. Infect. Dis. 50:1249-1251.
10. Kelly, C. A., C. J. C. J. Kotre, C. Ward, D. J. Hendrick, and E. H. Walters. 1987. Anatomical distribution of bronchoalveolar lavage fluid as assessed by digital subtraction radiography. Thorax 42:624-628. (Pubitemid 17118735)
11. Kidd, I. M., et al. 2009. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 374:1036.
12. McKimm-Breschkin, J., et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-2272. (Pubitemid 36753582)
13. Nguyen, H., T. A. M. Fry, P. A. Loveless, A. I. Klimov, and L. V. Gubareva. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51:983-984.
14. Peng, A., S. Miller, and D. Stein. 2000. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother. 44:1974-1976. (Pubitemid 30422958)
15. Rennard, S. I., et al. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538. (Pubitemid 16019939)
16. Stittelaar, K. J., et al. 2008. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res. 80:225-228.
17. van der Vries, E., F. F. Stelma, and C. A. B. Boucher. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382.
18. WHO. 9 June 2010, posting date. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 viruses. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/swineflu/ oseltamivirresistant20100611.pdf.